The Woodlands, TX, and Haifa, Israel, May 7, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America. The ADVA X3® is an advanced, fully automated platform for manufacturing cell therapies, streamlining processes and reducing costs. This alliance signifies a leap forward in personalized treatment, bringing cutting-edge therapies to patients worldwide.
The ADVA X3® is an all-in-one automated system that simplifies and accelerates the manufacturing of CAR-T therapies from manual to fully automated and cGMP in as little as three months. It represents a major advancement in manufacturing efficiency and quality control, ensuring the delivery of life-saving therapies with minimal user involvement. Moreover, the ADVA X3® significantly reduces costs, making it accessible to a broader patient population. The unique combination of Cellipont’s best-in-class process and manufacturing expertise and purpose-built facility coupled with the ADVA X3® metabolic sensing-based AI-driven automated manufacturing platform allows therapy developers to quickly go from manual processing to fully automated and GMP. Additionally, the ADVA X3® system supports cell therapies such as NK, TCR, TIL and exosomes from activation to final cell product.
“We’re proud to partner with Adva Biotechnology and be the first CDMO in North America to offer the ADVA X3® to clients. The ADVA X3’s automation and precision are game changers, enabling us to scale up production and meet the urgent needs of patients,” said Michael O’Mara, COO of Cellipont Bioservices.
“The collaboration with Cellipont Bioservices is a pivotal moment for us,” said Dr. Ohad Karnieli, CEO of Adva Biotechnology. “The ADVA X3® embodies our commitment to innovation and patient care, and with Cellipont’s expertise, we’re set to transform the landscape of cell therapies.”
Meet Us at ASGCT 2024 in Baltimore, MD
Both Cellipont Bioservices and Adva Biotechnology will be exhibiting at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place in Baltimore from May 7- 11, 2024. Attendees interested in learning more about the ADVA X3® system and exploring the latest advancements in cell therapy are encouraged to visit our booths (Cellipont Booth #1613, Adva Booth #1841). Representatives from both companies will be available to discuss our collaboration, answer questions, and share insights.
About Cellipont
Cellipont Bioservices is a premier Contract Development and Manufacturing Organization (CDMO) specializing in the advancement of cell therapy. With a team of industry-leading experts, Cellipont is at the forefront of cell therapy development and manufacturing, offering comprehensive solutions from process development, analytical services, to large-scale commercial manufacturing. Our purpose-built facility, combined with our cutting-edge technology and commitment to quality enable us to support our clients in delivering life-changing cell therapies to patients worldwide. Cellipont Bioservices is dedicated to excellence in all aspects of our operations, ensuring that we not only meet but exceed the expectations of our clients and the communities we serve. To learn more, visit www.cellipont.com.
About Adva Biotechnology
Adva Biotechnology is at the forefront of revolutionizing cell therapy manufacturing. By providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies. Their flagship product, the ADVA platform, is a fully controlled, flexible, and automated cell processing system. It leverages the unique CAMP (Continues Adaptive Multi-Parameter) technology, which streamlines autologous cell therapy manufacturing processes. Through automation, optical sensing, and artificial intelligence, Adva Biotechnology aims to remove the manual component from the process, ultimately advancing treatments for various forms of cancer and other conditions. Their commitment to improving patient outcomes through innovative technology underscores their mission: valuing life and advancing therapies. To learn more, visit www.advabio.com.
Cellipont Media Contact
Edwin Beale
ebeale@cellipont.com
Adva Biotechnology Media Contact
Ofra Toledo
VP, Business Development
ofra@advabio.com
ADVA Biotechnology and Cellipont Bioservices Showcase Accelerated Transition from R&D to GMP at Advanced Therapies Week 2025
BARLEV, ISRAEL, AND THE WOODLANDS, TEXAS, JANUARY 12, 2025– ADVA Biotechnology and Cellipont Bioservices are proud to announce their participation at Advanced Therapies Week 2025, taking place in Dallas, Texas, from January 20–23, 2025. Together, they will present a showcase study highlighting how their collaboration successfully transitioned a CAR-T process from a complex manual workflow to a streamlined, automated solution, achieving results with enhanced process control and consistency.
This study emphasizes the capabilities of the ADVA X3® Cell Manufacturing Platform, which simplifies and accelerates CAR-T manufacturing by integrating advanced in-process controls, AI, and machine learning. The platform enables a fast and seamless transition from R&D to GMP production while maintaining consistency, quality, and scalability.
Key Highlights of the Showcase Study:
“We are excited to present this showcase in collaboration with Cellipont Bioservices, whose unique expertise in process development and GMP manufacturing is crucial in accelerating CAR-T production,” said DR. OHAD KARNIELI, Founder and CEO of ADVA Biotechnology. “Together, we are demonstrating how the ADVA X3® platform, coupled with Cellipont’s unmatched expertise, can streamline the development and commercialization of cell therapies, bringing life-saving treatments to patients faster and more reliably.”
“We are proud to collaborate with ADVA Biotechnology to showcase the ADVA X3 platform,” said DARREN HEAD, CEO of Cellipont Bioservices. “Our efforts will improve the manufacturing of cell therapies, particularly CAR-T, by enhancing efficiency, reducing development time, and ensuring high-quality outcomes for patients.”
About Cellipont Bioservices:
Cellipont Bioservices is a premier Contract Development and Manufacturing Organization (CDMO) specializing in the advancement of cell therapies. With a team of industry-leading experts, Cellipont is at the forefront of cell therapy development and manufacturing, offering comprehensive solutions from process development, analytical services, to large-scale commercial manufacturing. Our purpose-built facility, combined with our cutting-edge technology and commitment to quality enable us to support our clients in delivering life-changing cell therapies to patients worldwide. Cellipont Bioservices is dedicated to excellence in all aspects of our operations, ensuring that we not only meet but exceed the expectations of our clients and the communities we serve. To learn more, visit www.cellipont.com.
About ADVA Biotechnology:
ADVA Biotechnology specializes in innovative cell therapy manufacturing solutions, offering scalable, flexible platforms that streamline production processes while maintaining the highest standards of quality and efficacy. Our flagship product, the ADVA X3 platform, is designed to support the entire manufacturing workflow, from research and development to GMP production, ensuring seamless integration and optimization across all stages. With a strong emphasis on AI and machine learning, ADVA Biotechnology delivers predictive analytics and adaptive process adjustments, enhancing the reliability and consistency of cell therapy outcomes. Our commitment to cutting-edge technology and excellence in execution positions ADVA Biotechnology as a leader in the industry, dedicated to advancing the field of cell therapy and bringing life-saving treatments to patients around the world. For more information, visit www.advabio.com.
ADVA Biotechnology Media Contact
OFRA TOLEDO
VICE PRESIDENT BUSINESS DEVELOPMENT
EMAIL: OFRA@ADVABIO.COM
Cellipont Bioservices Media Contact
EDWIN BEALE
CHIEF COMMERCIAL OFFICER
EMAIL: EBEALE@CELLIPONT.COM
ADVA Biotechnology Launches ADVA Select Module to Streamline Cell Selection and Incubation
January 20th, 2025, Dallas Texas, ADVA Biotechnology proudly announces the launch of the ADVA Select Module, a new addition to its suite of cell therapy manufacturing tools. Designed for cell selection and incubation in the upstream process, the ADVA Select seamlessly integrates with the ADVA X3 Cell Manufacturing Platform, simplifying workflows and enhancing production efficiency.
With the addition of the ADVA Select Module, ADVA Biotechnology now offers a complete end-to-end manufacturing solution, covering every stage of cell therapy production from selection to final processing. This ensures a streamlined, scalable, and cost-effective process tailored to a wide range of cell therapies, including CAR-T, TCR, NK, and more.
The ADVA Select Module will debut at ATW25 in Dallas, Texas, where ADVA Biotechnology will showcase its comprehensive approach to cell therapy manufacturing and its commitment to enhancing efficiency and accessibility.
“The ADVA Select Module is designed to streamline the upstream manufacturing process, helping our clients save time and resources while maintaining high-quality standards,” said Dr. Ohad Karnieli, Founder and CEO of ADVA Biotechnology.
For inquiries, please contact us at sales@advabio.com.
For more information, visit www.advabio.com.
About ADVA Biotechnology
ADVA Biotechnology specializes in advanced cell therapy manufacturing solutions, offering scalable and efficient platforms to meet the industry’s evolving needs.
Have any questions? Reach out to us from our contact form and we will get back to you shortly.